Bristol-Myers Squibb Company (BMY) investor relations material

Growth portfolio performance and outlook

• Growth portfolio delivered 12% year-over-year growth in Q1, with products like CAMZYOS, Reblozyl, and Breyanzi annualizing at over $1B, $1B, and $2B respectively.

• ELIQUIS continues to show double-digit growth, offsetting declines from legacy products facing generic competition.

• Ten new medicines and 30 lifecycle management indications are targeted for launch by 2030.

• The company expects to be among the fastest-growing in the sector by the end of the decade.

• Multiple catalysts are anticipated over the next 12-24 months, including key data readouts in Alzheimer's and bipolar disorders.

Product-specific updates and competitive dynamics

• CAMZYOS shows strong patient growth and persistency, aided by AI-driven diagnosis expansion and new prescriber adoption.

• New competition in the CAMZYOS market is being monitored, but no significant differentiation has been observed so far.

• Qvantig conversion rates have surpassed 10%, with a target of 30-40% over the next two years, and further acceleration expected with upcoming trial results.

• KRAZATI (Cobenfy) is experiencing steady growth in schizophrenia, with future acceleration expected from new indications.

Pipeline and clinical development

• A new phase III study in non-obstructive HCM is underway, aiming to address 30% of the market not currently served.

• Milvexian is positioned as a potential standard of care, aiming for superior bleeding profile over ELIQUIS and broad patient applicability.

• Secondary Stroke Prevention (SSP) and AFib indications for milvexian are seen as complementary, with data expected by year-end.

• Admilparant in IPF and PPF is viewed as a significant opportunity, with phase III results expected soon and potential for foundational and add-on use.

• CELMoDs (mezigdomide, iberdomide) are expected to replace older therapies in multiple myeloma, with strong community oncologist uptake anticipated.